PCR分析FISH与IHC检测人乳腺癌组织中HER―2表达差异性.docVIP

  • 6
  • 0
  • 约7.43千字
  • 约 11页
  • 2018-06-25 发布于福建
  • 举报

PCR分析FISH与IHC检测人乳腺癌组织中HER―2表达差异性.doc

PCR分析FISH与IHC检测人乳腺癌组织中HER―2表达差异性

PCR分析FISH与IHC检测人乳腺癌组织中HER―2表达差异性   【摘 要】目的:采用PCR技术分析人乳腺癌组织中FISH与IHC检测HER-2表达的差异性。方法:分别应用IHC、FISH、PCR,对185例乳腺浸润性导管癌病例进行HER-2状态检测,分析三者之间存在的差异性。结果:185例乳腺浸润性导管癌组织中,IHC 3+为72例(38.9%),其中FISH阳性60例(83.3%),PCR阳性66例(91.7%);IHC结果为2+时,FISH阳性19例(30.6%),PCR 21例(33.9%);IHC结果为0/l+时, FISH阳性4例(10%),PCR为3例(6.3%)。总体上,FISH检测HER-2基因阳性扩增例83(44.9%),阴性扩增102例(55.1%),与IHC检测结果基本相符(Kappa=0.728,P   【关键词】乳腺癌;HER-2;聚合酶链反应;荧光原位杂交;免疫组织化学   【中图分类号】R737.9 【文献标识码】A 【文章编号】1004-7484(2013)05-0051-02   To analyse comparatively the difference of HER-2 expressing in breast cancer by PCR, FISH and IHC   LV Haijun1, LI Feng1, WU Mingxia1, ZHAO Haifeng1, XIA Wei1, ZHU Xun2, FENG Yizhong1*   (1.Department of Pathology, 2.General Surgery Department, Soochow University Affiliated Second Hospital, Suzhou 215004, China)   【Abstract】Objectives:To analyse the difference of HER-2 gene amplification and protein expressing in breast cancer by polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), respectively. Methods:HER-2 gene amplifications and protein expressions in 185 cases of invasive ductal breast cancer were detected by PCR, FISH and IHC, comparatively, in which the differential characteristics were analysed.Results:HER-2 protein expressed by immunohistochemical scores of 3+ were 72 cases (38.9%), in which FISH positive amplifications were 60 (83.3%) and PCR positives were 66 (91.7%). When IHC scores were 2+, the positive rates of FISH and PCR were 30.6% (19) and 33.9% (21), and when scores 0/l+, the positive rates were 10% (4) and 6.3% (3), respectively. In total, HER-2 gene positive amplifications were 83 cases (44.9%) by FISH, which showed a coincidence rate with IHC (Kappa=0.728,P   【摘 要】目的:探讨培美曲塞单药治疗老年晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:21例经病理学确诊的晚期NSCLC接受培美曲塞单药化疗??2个周期后评价疗效及不良反应。结果:21例中,CR 0例,PR 6例,SD 10例,PD 5例,总有效率为28.6%(6/21)。主要毒副反应为骨髓抑制和乏力感,但可耐受。结论:培美曲塞治疗老年晚期NSCLC疗效较好,不良反应轻,可耐受。   【关键词】培美曲塞;老年患者;非小细胞肺癌   【中图分类号】R734.2 【文献标识码】A 【文章编号】1004-7484(2013)05-004

文档评论(0)

1亿VIP精品文档

相关文档